Project Grant R21AI203620
Award Date 8/18/26
Completion Date 7/31/28
Dollars Obligated $278K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $220,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a dual germline-targeting immunization strategy eliciting broadly neutralizing antibodies against HIV-1. The research uses preclinical transgenic mouse models and data from an ongoing Phase 1 clinical trial (HVTN301) to optimize a prime-boost vaccination approach with the germline-targeting...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $3.55 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 12, 2025, with a completion date of August 31, 2029. The grant funds research assessing the effects of oral pre-exposure prophylaxis (PrEP) on the pharmacokinetics of monoclonal antibodies and vaccine-induced antibodies among...
- The National Institute of Allergy and Infectious Diseases awarded New York University $841,719 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop low-cost rapid antibody tests for monitoring HIV treatment effectiveness as a complement to conventional PCR viral load testing. The research consolidates quantitative antibody data across 13 assay platforms and 17 longitudinal HIV treatment cohorts spanning 10 countries and all major HIV subtypes. The...
- The National Institute of Allergy and Infectious Diseases awarded $1.744 million to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the MAATCH project—Modeling Antibody Approaches for a Tailored Cure for HIV. The award funds laboratory-based experiments and mathematical modeling to determine the degree of personalization required to advance antibody-based HIV...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $236,444 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the persistence of HIV-specific B cells in early-treated Thai children after long-term antiretroviral therapy. The research characterizes HIV-specific humoral immune responses in children from the Thai HIV-NAT209 cohort who initiated antiretroviral therapy early after perinatal...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $323,892 on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research training program in mathematical modeling of SARS-CoV-2 variant emergence from immunocompromised hosts. The award funds development of a suite of mathematical models to understand mechanisms facilitating generation of SARS-CoV-2 variants of concern during prolonged...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $238,899 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical evaluation of human monoclonal antibodies for herpes simplex virus type 2 (HSV-2) therapeutics. The research isolates and characterizes antibody-secreting cells discovered in genital skin tissue up to four months following HSV lesion healing. The project involves comprehensive...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $670,230 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop rapid enzymatic assays for point-of-care HIV drug-level feedback. The award is classified as a Project Grant (R01AI195093). The research addresses adherence barriers among adolescent girls and young women in sub-Saharan Africa, who account for one in four new HIV infections globally. Current...
- The National Institute of Allergy and Infectious Diseases awarded The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., $317,272 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a structure-based sieve analysis pipeline for understanding antibody-mediated immunity in HIV-1 vaccine and monoclonal antibody prevention trials. The award funds two aims: development of a structure-based sieve analysis framework that...